The prevalence of anemia in chronic heart failure

被引:134
作者
Tanner, H [1 ]
Moschovitis, G [1 ]
Kuster, GM [1 ]
Hullin, R [1 ]
Pfiffner, D [1 ]
Hess, OM [1 ]
Mohacsi, P [1 ]
机构
[1] Univ Hosp Bern, Inselspital, Swiss Cardiovasc Ctr, CH-3010 Bern, Switzerland
关键词
D O I
10.1016/S0167-5273(02)00273-5
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objectives: To assess prevalence of anemia and its correlation with NYHA-class in patients with congestive heart failure. Background: Recently, it was reported that anemia in congestive heart failure patients is common and correlated with the severity of disease. In these patients with anemia, treatment with erythropoietin and intravenous iron improved cardiac function significantly. Methods: 193 patients from a tertiary heart failure outpatient clinic (mean age 54 years) were included in a retrospective analysis. Fourteen patients were in NYHA-class I, 69 class II, 79 class III, and 31 class IV All patients had clinical and laboratory evaluation, echocardiography and coronary angiography. Patients with secondary anemia or on hemodialysis were excluded. Etiology of heart failure was ischemic in 41 %. Results: Anemia (hemoglobin < 120 g/l) was present in 28 of 193 patients (15%). There was an inverse relationship between NYHA-class and left ventricular ejection fraction (NYHA-class I 45%, class II 32%, class III 25%, class IV 25%). Serum creatinine increased with NYHA-class. Hemoglobin levels were similar in all four NYHA-classes but there were significantly more patients with anemia in NYHA-class III and IV (19%) compared with class I and II (8%, P<0.05). Hemoglobin was similar in surviving patients (mean 140 g/l) and those who died or were transplanted (mean 136 g/l, ns). Conclusions: The prevalence of anemia in our heart failure service is 15% (compared with 56% in the literature) and is correlated to NYHA-class. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:115 / 121
页数:7
相关论文
共 29 条
[1]
ABBOUD C, 1995, WILLIAMS HEMATOLOGY, V1, P25
[2]
Al-Ahmad A., 2000, Journal of the American Society of Nephrology, V11, p137A
[3]
ANAND IS, 1993, BRIT HEART J, V70, P357
[4]
[Anonymous], 2001, AM J KIDNEY DIS, V37, pS182
[5]
Anemia and aging: an overview of clinical, diagnostic and biological issues [J].
Carmel, R .
BLOOD REVIEWS, 2001, 15 (01) :9-18
[6]
Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT1 antagonists [J].
Chatterjee, B ;
Nydegger, UE ;
Mohacsi, P .
EUROPEAN JOURNAL OF HEART FAILURE, 2000, 2 (04) :393-398
[7]
[8]
Kojima K, 1989, Nihon Ronen Igakkai Zasshi, V26, P160
[9]
Renal anaemia treatment with recombinant human erythropoietin increases cardiac output in patients with ischaemic heart disease [J].
Linde, T ;
Wikstrom, B ;
Andersson, LG ;
Danielson, BG .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1996, 30 (02) :115-120
[10]
The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy Dialysis Registry [J].
Locatelli, F ;
Conte, F ;
Marcelli, D .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (07) :1642-1644